Business
Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neuroscience Education Institute (NEI) conferences. “We’re proud to present new real-world data at both AACAP and NEI during ADHD Awareness Month, underscoring our continued commitment to the ADHD community. These presentations offer meaningful insight into the real-world use of Jornay PM and support our mission to improve care for individuals living with ADHD,” said Thomas Smith, M.D., Chief Medical Officer. AACAP is being held in Chicago, IL from October 20-25, 2025. Poster Title:Determining the Optimal Dose of Methylphenidate HCI (JORNAY PM) in Adolescents and Adults in a Real-World Psychiatric SettingAuthors:Joel Young, MD; Richard Powell, PhD, JD, LPC, CCMHC; Anna Powell, MS; Lauren Granata, PhD; Lisa Welling, PhD; Jaime Saal, MA, LPC, NCC; Margot Nash, MADate:Time:Location:Wednesday, October 224 – 6 p.m. CDTHyatt Regency NEI Fall Congress is being held in Colorado Springs, CO from November 6-9, 2025. Poster Title:JORNAY PM®in Practice: Real-World Evidence Exploration of Utilization and Patient ResponseAuthors:Joel Young, MD; Richard Powell, PhD, JD, LPC, CCMHC; Anna Powell, MS; Lauren Granata, PhD; Lisa Welling, PhD; Jaime Saal, MA, LPC, NCC; Margot Nash, MADate:Time:Location:Friday, November 74 – 5 p.m. MSTBroadmoor West, The Broadmoor IMPORTANT SAFETY INFORMATION JORNAY PM is a federally controlled substance (CII) because it contains methylphenidate and has a high chance of abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of JORNAY PM can lead to overdose and death, which is increased with higher doses of JORNAY PM or if it is used in ways that are not approved, such as snorting or injection. Your healthcare provider (HCP) should check for signs of abuse, misuse, and addiction before starting and during treatment with JORNAY PM. JORNAY PM may lead to physical dependence after prolonged use, even if taken as dir...